Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$44 Mln
P/E Ratio
--
P/B Ratio
218.61
Industry P/E
--
Debt to Equity
0
ROE
-12.79 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
-11.21
CFO
$-937.90 Mln
EBITDA
$-858.53 Mln
Net Profit
$-1,538.99 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Agenus (AGEN)
| -39.05 | -52.01 | -39.49 | 196.84 | -16.85 | -3.65 | -11.15 |
|
BSE Sensex*
| -2.20 | 1.05 | -1.94 | 6.14 | 9.77 | 20.67 | 10.48 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Agenus (AGEN)
| 226.92 | -64.76 | -25.47 | 1.26 | -21.87 | 71.01 | -26.87 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.18 | 10,372.39 | 21.06 | 23.13 | |
| 32.45 | 12,882.28 | -- | -28.77 | |
| 110.07 | 10,998.29 | 33.53 | 14.16 | |
| 73.45 | 7,759.66 | 34.18 | 19.71 |
Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally. It offers Retrocyte Display, an antibody expression... platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract t; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts. Address: 3 Forbes Road, Lexington, MA, United States, 02421-7305 Read more
Founder, Executive Chairman & CEO
Dr. Garo H. Armen Ph.D.
Founder, Executive Chairman & CEO
Dr. Garo H. Armen Ph.D.
Headquarters
Lexington, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Agenus Inc (AGEN) stood at $ 509 Mln as on 30-Sep-24
The share price of Agenus Inc (AGEN) is $1.67 (NASDAQ) as of 20-Mar-2025 16:15 EDT. Agenus Inc (AGEN) has given a return of -16.85% in the last 3 years.
Agenus Inc (AGEN) has a market capitalisation of $ 44 Mln as on 20-Mar-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Agenus Inc (AGEN) is 218.61 times as on 20-Mar-2025, a 7967% premium to its peers’ median range of 2.71 times.
Since, TTM earnings of Agenus Inc (AGEN) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Agenus Inc (AGEN) and enter the required number of quantities and click on buy to purchase the shares of Agenus Inc (AGEN).
Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract t; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts. Address: 3 Forbes Road, Lexington, MA, United States, 02421-7305
The CEO & director of Dr. Garo H. Armen Ph.D.. is Agenus Inc (AGEN), and CFO & Sr. VP is Dr. Garo H. Armen Ph.D..
There is no promoter pledging in Agenus Inc (AGEN).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,168
|
|
|
1,141
|
|
|
1,072
|
|
|
1,045
|
| Agenus Inc. (AGEN) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
-57.92
|
|
Net Margin(%)
|
-141.9
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Agenus Inc (AGEN) was $0 Mln.
$-0.06
(
